Bio-Techne's (TECH) Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test

Go back to Bio-Techne's (TECH) Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test

Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test

March 23, 2021 7:00 AM EDT

MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic (IVD) version of the ExoDx Prostate test (EPI) kit enabling self-certification as CE-IVD as of March 22, 2021. The EPI-CE test will be performed immediately in our Munich ISO 15189 accredited clinical laboratory and be made available throughout Europe through various distribution channels.

Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that helps... More